Promising Clinical Efficacy of Streptomycin-Rifampin Combination for Treatment of Buruli Ulcer (Mycobacterium ulcerans Disease)
Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit StumbleUpon Twitter current issue AAC About AAC Subscribers Authors Reviewers Advertisers Inquiries from the Press Permissions & Commerc...
Saved in:
| Published in: | Antimicrobial Agents and Chemotherapy Vol. 51; no. 11; pp. 4029 - 4035 |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
Washington, DC
American Society for Microbiology
01-11-2007
American Society for Microbiology (ASM) |
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Classifications
Services
AAC
Citing Articles
Google Scholar
PubMed
Related Content
Social Bookmarking
CiteULike
Delicious
Digg
Facebook
Google+
Mendeley
Reddit
StumbleUpon
Twitter
current issue
AAC
About
AAC
Subscribers
Authors
Reviewers
Advertisers
Inquiries from the Press
Permissions & Commercial Reprints
ASM Journals Public Access Policy
AAC
RSS Feeds
1752 N Street N.W. • Washington DC 20036
202.737.3600 • 202.942.9355 fax • journals@asmusa.org
Print ISSN:
0066-4804
Online ISSN:
1098-6596
Copyright © 2014
by the
American Society for Microbiology.
For an alternate route to
AAC
.asm.org, visit:
AAC
|
|---|---|
| AbstractList | ABSTRACT
According to recommendations of the 6th WHO Advisory Committee on Buruli ulcer, directly observed treatment with the combination of rifampin and streptomycin, administered daily for 8 weeks, was recommended to 310 patients diagnosed with Buruli ulcer in Pobè, Bénin. Among the 224 (72%) eligible patients for whom treatment was initiated, 215 (96%) were categorized as treatment successes, and 9, including 1 death and 8 losses to follow-up, were treatment failures. Of the 215 successfully treated patients, 102 (47%) were treated exclusively with antibiotics and 113 (53%) were treated with antibiotics plus surgical excision and skin grafting. The size of lesions at treatment initiation was the major factor associated with surgical intervention: 73% of patients with lesions of >15 cm in diameter underwent surgery, whereas only 17% of patients with lesions of <5 cm had surgery. No patient discontinued therapy for side effects from the antibiotic treatment. One year after stopping treatment, 208 of the 215 patients were actively retrieved to assess the long-term therapeutic results: 3 (1.44%) of the 208 retrieved patients had recurrence of
Mycobacterium ulcerans
disease, 2 among the 107 patients treated only with antibiotics and 1 among the 108 patients treated with antibiotics plus surgery. We conclude that the WHO-recommended streptomycin-rifampin combination is highly efficacious for treating
M. ulcerans
disease. Chemotherapy alone was successful in achieving cure in 47% of cases and was particularly effective against ulcers of less than 5 cm in diameter. Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit StumbleUpon Twitter current issue AAC About AAC Subscribers Authors Reviewers Advertisers Inquiries from the Press Permissions & Commercial Reprints ASM Journals Public Access Policy AAC RSS Feeds 1752 N Street N.W. • Washington DC 20036 202.737.3600 • 202.942.9355 fax • journals@asmusa.org Print ISSN: 0066-4804 Online ISSN: 1098-6596 Copyright © 2014 by the American Society for Microbiology. For an alternate route to AAC .asm.org, visit: AAC According to recommendations of the 6th WHO Advisory Committee on Buruli ulcer, directly observed treatment with the combination of rifampin and streptomycin, administered daily for 8 weeks, was recommended to 310 patients diagnosed with Buruli ulcer in Pobe, Benin. Among the 224 (72%) eligible patients for whom treatment was initiated, 215 (96%) were categorized as treatment successes, and 9, including 1 death and 8 losses to follow-up, were treatment failures. Of the 215 successfully treated patients, 102 (47%) were treated exclusively with antibiotics and 113 (53%) were treated with antibiotics plus surgical excision and skin grafting. The size of lesions at treatment initiation was the major factor associated with surgical intervention: 73% of patients with lesions of >15 cm in diameter underwent surgery, whereas only 17% of patients with lesions of <5 cm had surgery. No patient discontinued therapy for side effects from the antibiotic treatment. One year after stopping treatment, 208 of the 215 patients were actively retrieved to assess the long-term therapeutic results: 3 (1.44%) of the 208 retrieved patients had recurrence of Mycobacterium ulcerans disease, 2 among the 107 patients treated only with antibiotics and 1 among the 108 patients treated with antibiotics plus surgery. We conclude that the WHO-recommended streptomycin-rifampin combination is highly efficacious for treating M. ulcerans disease. Chemotherapy alone was successful in achieving cure in 47% of cases and was particularly effective against ulcers of less than 5 cm in diameter. According to recommendations of the 6th WHO Advisory Committee on Buruli ulcer, directly observed treatment with the combination of rifampin and streptomycin, administered daily for 8 weeks, was recommended to 310 patients diagnosed with Buruli ulcer in Pobè, Bénin. Among the 224 (72%) eligible patients for whom treatment was initiated, 215 (96%) were categorized as treatment successes, and 9, including 1 death and 8 losses to follow-up, were treatment failures. Of the 215 successfully treated patients, 102 (47%) were treated exclusively with antibiotics and 113 (53%) were treated with antibiotics plus surgical excision and skin grafting. The size of lesions at treatment initiation was the major factor associated with surgical intervention: 73% of patients with lesions of >15 cm in diameter underwent surgery, whereas only 17% of patients with lesions of <5 cm had surgery. No patient discontinued therapy for side effects from the antibiotic treatment. One year after stopping treatment, 208 of the 215 patients were actively retrieved to assess the long-term therapeutic results: 3 (1.44%) of the 208 retrieved patients had recurrence of Mycobacterium ulcerans disease, 2 among the 107 patients treated only with antibiotics and 1 among the 108 patients treated with antibiotics plus surgery. We conclude that the WHO-recommended streptomycin-rifampin combination is highly efficacious for treating M. ulcerans disease. Chemotherapy alone was successful in achieving cure in 47% of cases and was particularly effective against ulcers of less than 5 cm in diameter. According to recommendations of the 6th WHO Advisory Committee on Buruli ulcer, directly observed treatment with the combination of rifampin and streptomycin, administered daily for 8 weeks, was recommended to 310 patients diagnosed with Buruli ulcer in Pobè, Bénin. Among the 224 (72%) eligible patients for whom treatment was initiated, 215 (96%) were categorized as treatment successes, and 9, including 1 death and 8 losses to follow-up, were treatment failures. Of the 215 successfully treated patients, 102 (47%) were treated exclusively with antibiotics and 113 (53%) were treated with antibiotics plus surgical excision and skin grafting. The size of lesions at treatment initiation was the major factor associated with surgical intervention: 73% of patients with lesions of >15 cm in diameter underwent surgery, whereas only 17% of patients with lesions of <5 cm had surgery. No patient discontinued therapy for side effects from the antibiotic treatment. One year after stopping treatment, 208 of the 215 patients were actively retrieved to assess the long-term therapeutic results: 3 (1.44%) of the 208 retrieved patients had recurrence of Mycobacterium ulcerans disease, 2 among the 107 patients treated only with antibiotics and 1 among the 108 patients treated with antibiotics plus surgery. We conclude that the WHO-recommended streptomycin-rifampin combination is highly efficacious for treating M. ulcerans disease. Chemotherapy alone was successful in achieving cure in 47% of cases and was particularly effective against ulcers of less than 5 cm in diameter. According to recommendations of the 6th WHO Advisory Committee on Buruli ulcer, directly observed treatment with the combination of rifampin and streptomycin, administered daily for 8 weeks, was recommended to 310 patients diagnosed with Buruli ulcer in Pobè, Bénin. Among the 224 (72%) eligible patients for whom treatment was initiated, 215 (96%) were categorized as treatment successes, and 9, including 1 death and 8 losses to follow-up, were treatment failures. Of the 215 successfully treated patients, 102 (47%) were treated exclusively with antibiotics and 113 (53%) were treated with antibiotics plus surgical excision and skin grafting. The size of lesions at treatment initiation was the major factor associated with surgical intervention: 73% of patients with lesions of >15 cm in diameter underwent surgery, whereas only 17% of patients with lesions of <5 cm had surgery. No patient discontinued therapy for side effects from the antibiotic treatment. One year after stopping treatment, 208 of the 215 patients were actively retrieved to assess the long-term therapeutic results: 3 (1.44%) of the 208 retrieved patients had recurrence of Mycobacterium ulcerans disease, 2 among the 107 patients treated only with antibiotics and 1 among the 108 patients treated with antibiotics plus surgery. We conclude that the WHO-recommended streptomycin-rifampin combination is highly efficacious for treating M. ulcerans disease. Chemotherapy alone was successful in achieving cure in 47% of cases and was particularly effective against ulcers of less than 5 cm in diameter. |
| Author | Ambroise Adeye Christian Johnson Jacques Grosset Augustin Guédénon Hélène Euverte Marie-Françoise Ardant Jacques Aubry Annick Chauty Eric Nuermberger |
| AuthorAffiliation | Centre de Dépistage et de Traitement de l'ulcère de Buruli, Pobè, Bénin, 1 Buruli Ulcer Control Programme, Cotonou, Bénin, 2 Fondation Raoul Follereau, Paris, France, 3 University Nantes, Faculty of Pharmacy, F-44093, Inserm, U601, Nantes, France, 4 Johns Hopkins University School of Medicine, Center for Tuberculosis Research, Baltimore, Maryland 5 |
| AuthorAffiliation_xml | – name: Centre de Dépistage et de Traitement de l'ulcère de Buruli, Pobè, Bénin, 1 Buruli Ulcer Control Programme, Cotonou, Bénin, 2 Fondation Raoul Follereau, Paris, France, 3 University Nantes, Faculty of Pharmacy, F-44093, Inserm, U601, Nantes, France, 4 Johns Hopkins University School of Medicine, Center for Tuberculosis Research, Baltimore, Maryland 5 |
| Author_xml | – sequence: 1 givenname: Annick surname: CHAUTY fullname: CHAUTY, Annick organization: Centre de Dépistage et de Traitement de l'ulcère de Buruli, Pobè, Benin – sequence: 2 givenname: Marie-Francoise surname: ARDANT fullname: ARDANT, Marie-Francoise organization: Centre de Dépistage et de Traitement de l'ulcère de Buruli, Pobè, Benin – sequence: 3 givenname: Ambroise surname: ADEYE fullname: ADEYE, Ambroise organization: Centre de Dépistage et de Traitement de l'ulcère de Buruli, Pobè, Benin – sequence: 4 givenname: Hélène surname: EUVERTE fullname: EUVERTE, Hélène organization: Centre de Dépistage et de Traitement de l'ulcère de Buruli, Pobè, Benin – sequence: 5 givenname: Augustin surname: GUEDENON fullname: GUEDENON, Augustin organization: Fondation Raoul Follereau, Paris, France – sequence: 6 givenname: Christian surname: JOHNSON fullname: JOHNSON, Christian organization: Buruli Ulcer Control Programme, Cotonou, Benin – sequence: 7 givenname: Jacques surname: AUBRY fullname: AUBRY, Jacques organization: University Nantes, Faculty of Pharmacy, Inserm, U601, 44093 Nantes, France – sequence: 8 givenname: Eric surname: NUERMBERGER fullname: NUERMBERGER, Eric organization: Johns Hopkins University School of Medicine, Center for Tuberculosis Research, Baltimore, Maryland, United States – sequence: 9 givenname: Jacques surname: GROSSET fullname: GROSSET, Jacques organization: Johns Hopkins University School of Medicine, Center for Tuberculosis Research, Baltimore, Maryland, United States |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=19204194$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/17526760$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkstv1DAQxi1URLeFG2dkIYGoRMo4cR6-IC2hPKQiELRna-LYu64Se7ET0J741_GyKwoHxGlkz8_fPD6fkCPnnSbkIYNzxvLmBaI6B2B1mUF9hywYiCarSlEdkQVAVWW8AX5MTmK8gXQuBdwjx4nOq7qCBfnxKfjRRutWtB2sswoHemFMimpLvaFfpqA3kx-3yrrsszU4bqyjrR8763Cy3lHjA70KGqdRu2n35NUc5sHS60HpQJ992CrfoZp0sPNI590lukhf26gx6rP75K7BIeoHh3hKrt9cXLXvssuPb9-3y8sMeVPWmYaiF2CgQw4560vsco66b3LR933XlxqY4T3mDda6M73udAmosOecYQFNXZySl3vdzdyNulep14CD3AQ7YthKj1b-nXF2LVf-m8xZyTiIJPD0IBD811nHSaa1KT0M6LSfo6wazlgq9V-QCSGKnBUJfL4HVfAxBm1-d8NA7qyVy2Urf1krYTfB2R7HOObyxs_BpYX9i33057S3wgffE_DkAGBMlpvkibLxlhM5cCZ44h7vubVdrb_boGWqLtOXkyVLdWVyQxQ_AUUwyUM |
| CODEN | AACHAX |
| CitedBy_id | crossref_primary_10_1128_AAC_02853_15 crossref_primary_10_1371_journal_pntd_0001590 crossref_primary_10_1111_tmi_12745 crossref_primary_10_5694_mja13_11331 crossref_primary_10_1016_j_trstmh_2008_06_006 crossref_primary_10_1371_journal_pntd_0000380 crossref_primary_10_1007_s00430_009_0109_6 crossref_primary_10_1186_2049_9957_1_6 crossref_primary_10_1002_chem_201503122 crossref_primary_10_1177_0308518X15599289 crossref_primary_10_1002_JLB_MR0318_128 crossref_primary_10_1128_aac_01902_21 crossref_primary_10_1039_b801397g crossref_primary_10_1371_journal_pntd_0001237 crossref_primary_10_1002_14651858_CD012118_pub2 crossref_primary_10_3201_eid1604_090195 crossref_primary_10_1371_journal_pntd_0002968 crossref_primary_10_1371_journal_pntd_0001473 crossref_primary_10_1517_14656560903369363 crossref_primary_10_1016_j_clindermatol_2008_09_021 crossref_primary_10_1093_cid_ciq072 crossref_primary_10_1097_QCO_0b013e32833c2209 crossref_primary_10_1371_journal_ppat_1009107 crossref_primary_10_1371_journal_pntd_0001228 crossref_primary_10_1371_journal_pntd_0000933 crossref_primary_10_1016_j_antib_2009_09_007 crossref_primary_10_1128_CVI_00235_08 crossref_primary_10_1371_journal_pntd_0006238 crossref_primary_10_1080_14737159_2018_1543592 crossref_primary_10_1080_00206811003679737 crossref_primary_10_1371_journal_pntd_0000770 crossref_primary_10_1371_journal_pone_0032740 crossref_primary_10_1128_AAC_05543_11 crossref_primary_10_1111_j_1445_2197_2012_06230_x crossref_primary_10_1371_journal_pntd_0006358 crossref_primary_10_1371_journal_pntd_0009454 crossref_primary_10_1371_journal_pntd_0011413 crossref_primary_10_1128_IAI_00820_10 crossref_primary_10_1093_cid_cir856 crossref_primary_10_4269_ajtmh_14_0571 crossref_primary_10_1128_AAC_00400_10 crossref_primary_10_5694_j_1326_5377_2009_tb03313_x crossref_primary_10_1016_j_annder_2014_01_010 crossref_primary_10_1371_journal_pntd_0004603 crossref_primary_10_1586_erv_09_87 crossref_primary_10_1371_journal_pntd_0007317 crossref_primary_10_1371_journal_pntd_0001334 crossref_primary_10_1016_j_tube_2009_07_002 crossref_primary_10_1128_AAC_03874_14 crossref_primary_10_1128_JCM_01842_08 crossref_primary_10_1051_medsci_20132910021 crossref_primary_10_1371_journal_pntd_0002809 crossref_primary_10_1007_s40506_018_0174_8 crossref_primary_10_1111_j_1365_2133_2008_08879_x crossref_primary_10_1371_journal_pntd_0006291 crossref_primary_10_5025_hansen_91_55 crossref_primary_10_1016_j_vascn_2015_03_001 crossref_primary_10_1016_j_det_2010_09_006 crossref_primary_10_1016_j_clinmicnews_2009_07_004 crossref_primary_10_1016_j_banm_2023_07_013 crossref_primary_10_1016_S1473_3099_18_30160_9 crossref_primary_10_1371_journal_pntd_0002010 crossref_primary_10_1371_journal_pntd_0004431 crossref_primary_10_1111_1346_8138_12851 crossref_primary_10_1111_tmi_12342 crossref_primary_10_1016_S1473_3099_13_70201_9 crossref_primary_10_1093_bmb_ldp046 crossref_primary_10_1007_s40257_015_0138_4 crossref_primary_10_1186_1471_2458_12_264 crossref_primary_10_1128_AAC_01260_10 crossref_primary_10_1016_S0140_6736_09_61962_0 crossref_primary_10_1016_S0140_6736_10_60169_9 crossref_primary_10_1002_14651858_CD012118 crossref_primary_10_1016_j_jep_2015_06_024 crossref_primary_10_1371_journal_pntd_0006728 crossref_primary_10_1021_cr1002563 crossref_primary_10_1128_CMR_00045_17 crossref_primary_10_11124_JBISRIR_2016_003235 crossref_primary_10_1128_JCM_00558_10 crossref_primary_10_3389_fmicb_2023_1266261 crossref_primary_10_1128_AAC_00193_08 crossref_primary_10_1586_14787210_2014_910113 crossref_primary_10_1039_c3np70068b crossref_primary_10_1111_j_1365_3156_2009_02324_x crossref_primary_10_2217_fmb_11_101 crossref_primary_10_1371_journal_pntd_0004011 crossref_primary_10_1111_j_1751_0813_2011_00850_x crossref_primary_10_1093_infdis_jiab236 crossref_primary_10_1177_1534734615599653 crossref_primary_10_1097_INF_0000000000000061 crossref_primary_10_1371_journal_pone_0231685 crossref_primary_10_1371_journal_pntd_0000731 crossref_primary_10_1371_journal_pntd_0000216 crossref_primary_10_1371_journal_pntd_0000736 crossref_primary_10_1371_journal_pntd_0003606 crossref_primary_10_1371_journal_pntd_0003200 crossref_primary_10_1371_journal_pntd_0007126 crossref_primary_10_1371_journal_pntd_0002598 crossref_primary_10_1111_j_1365_3156_2007_01990_x crossref_primary_10_2174_1871526522666220919105643 crossref_primary_10_1016_j_lpm_2011_10_018 crossref_primary_10_4269_ajtmh_2011_11_0429 crossref_primary_10_1016_S0140_6736_20_30478_5 crossref_primary_10_1016_S1761_2896_16_78235_5 crossref_primary_10_1128_JCM_00197_09 crossref_primary_10_1111_ans_14829 crossref_primary_10_1007_s40257_018_0382_5 crossref_primary_10_1128_JCM_02279_10 crossref_primary_10_1016_j_vaccine_2015_03_046 crossref_primary_10_1016_j_jaad_2009_09_055 crossref_primary_10_4269_ajtmh_14_0405 crossref_primary_10_1007_s13149_009_0002_y crossref_primary_10_3201_eid1403_070904 crossref_primary_10_1128_AAC_00011_09 crossref_primary_10_3201_eid1604_091343 crossref_primary_10_1016_j_micinf_2010_09_002 crossref_primary_10_1128_AAC_02165_13 crossref_primary_10_1371_journal_pntd_0001252 crossref_primary_10_1371_journal_pntd_0005695 crossref_primary_10_1371_journal_pone_0051074 crossref_primary_10_1128_AAC_00730_07 crossref_primary_10_1155_2016_8304524 crossref_primary_10_1155_2012_752749 crossref_primary_10_3390_toxins11060346 crossref_primary_10_1186_s40249_016_0119_8 crossref_primary_10_1371_journal_pntd_0004594 crossref_primary_10_1517_14712590802631854 crossref_primary_10_1371_journal_pntd_0003549 crossref_primary_10_1371_journal_pntd_0002612 crossref_primary_10_1007_s15010_008_8073_4 crossref_primary_10_1128_AAC_00299_10 crossref_primary_10_1371_journal_pntd_0001925 crossref_primary_10_1371_journal_pntd_0002618 crossref_primary_10_1016_j_trstmh_2011_05_003 crossref_primary_10_1371_journal_pntd_0003421 crossref_primary_10_3201_eid1311_061206 crossref_primary_10_1371_journal_pntd_0003941 crossref_primary_10_1016_j_medmal_2009_08_021 crossref_primary_10_1371_journal_pntd_0000553 |
| Cites_doi | 10.1128/AAC.49.8.3182-3186.2005 10.1128/IAI.72.1.62-65.2004 10.1128/AAC.46.10.3193-3196.2002 10.1128/IAI.68.2.877-883.2000 10.1128/AAC.00052-06 10.1016/S0140-6736(99)01156-3 10.1128/AAC.45.11.3109-3112.2001 10.1128/AAC.42.8.2070 10.1128/JCM.38.4.1482-1487.2000 10.1093/jac/45.2.231 10.1016/0140-6736(90)92581-2 10.1001/archderm.1974.01630110073023 10.1128/AAC.47.4.1228-1232.2003 10.3201/eid1104.041000 10.1128/jcm.35.7.1696-1700.1997 10.1128/JCM.37.4.1018-1023.1999 10.1128/AAC.44.9.2367-2372.2000 10.1016/S1473-3099(06)70464-9 10.1126/science.283.5403.854 10.1016/S0924-8579(03)00240-1 |
| ContentType | Journal Article |
| Copyright | 2007 INIST-CNRS Copyright © 2007 American Society for Microbiology Copyright © 2007, American Society for Microbiology |
| Copyright_xml | – notice: 2007 INIST-CNRS – notice: Copyright © 2007 American Society for Microbiology – notice: Copyright © 2007, American Society for Microbiology |
| DBID | IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 7QL 7T7 8FD C1K FR3 P64 7X8 5PM |
| DOI | 10.1128/aac.00175-07 |
| DatabaseName | Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Bacteriology Abstracts (Microbiology B) Industrial and Applied Microbiology Abstracts (Microbiology A) Technology Research Database Environmental Sciences and Pollution Management Engineering Research Database Biotechnology and BioEngineering Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Engineering Research Database Technology Research Database Industrial and Applied Microbiology Abstracts (Microbiology A) Bacteriology Abstracts (Microbiology B) Biotechnology and BioEngineering Abstracts Environmental Sciences and Pollution Management MEDLINE - Academic |
| DatabaseTitleList | CrossRef Engineering Research Database MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: ECM name: MEDLINE url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology Biology |
| EISSN | 1098-6596 |
| EndPage | 4035 |
| ExternalDocumentID | 10_1128_AAC_00175_07 0175-07 17526760 19204194 aac_51_11_4029 |
| Genre | Clinical Trial Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- .55 .GJ 08R 0R~ 23M 2WC 39C 3O- 4.4 53G 5GY 5RE 5VS 6J9 AAPBV AAUGY ACGFO ADBBV AENEX AFMIJ AGNAY AI. ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BTFSW C1A CS3 DIK E3Z EBS EJD F5P FRP GX1 H13 HH5 HYE HZ~ H~9 IQODW J5H K-O KQ8 L7B LSO MVM NEJ O9- OK1 P2P RHF RHI RNS RPM RSF TR2 UHB VH1 W2D W8F WH7 WHG WOQ X7M X7N XOL Y6R ZA5 ZGI ZXP ~A~ AGVNZ CGR CUY CVF ECM EIF NPM - 0R 55 A ABFLS ADACO ADBIT BXI GJ HZ AAYXX CITATION 7QL 7T7 8FD C1K FR3 P64 7X8 5PM |
| ID | FETCH-LOGICAL-a4857-e03d90f0ba4021d5ab24aed829dddbd5e01f4da28a7ebfdebe50acad441a30873 |
| IEDL.DBID | RPM |
| ISSN | 0066-4804 |
| IngestDate | Tue Sep 17 21:06:07 EDT 2024 Sat Oct 26 05:40:40 EDT 2024 Sun Sep 29 07:19:04 EDT 2024 Thu Sep 12 17:51:02 EDT 2024 Tue Dec 28 13:59:01 EST 2021 Sat Nov 02 12:22:10 EDT 2024 Sun Oct 22 16:06:01 EDT 2023 Wed May 18 15:35:05 EDT 2016 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 11 |
| Keywords | Skin disease Streptomycin Treatment efficiency Mycobacterial infection Rifamycin Infection Antibiotic Mycobacterium ulcerans Rifampicin Treatment Mycobacteriales Buruli ulcer Aminoglycoside Bacteriosis Mycobacteriaceae Bacteria Actinomycetes Antituberculous agent Protein synthesis inhibitor Antibacterial agent |
| Language | English |
| License | CC BY 4.0 |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-a4857-e03d90f0ba4021d5ab24aed829dddbd5e01f4da28a7ebfdebe50acad441a30873 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Article-2 ObjectType-Feature-1 Corresponding author. Mailing address: Center for Tuberculosis Research, Johns Hopkins University School of Medicine, 1550 Orleans Street, Baltimore, MD 21231-1001. Phone: (410) 502-8234. Fax: (410) 614-8173. E-mail: jgrosse4@jhmi.edu |
| OpenAccessLink | https://doi.org/10.1128/aac.00175-07 |
| PMID | 17526760 |
| PQID | 19993213 |
| PQPubID | 23462 |
| PageCount | 7 |
| ParticipantIDs | pubmed_primary_17526760 asm2_journals_10_1128_AAC_00175_07 proquest_miscellaneous_68411308 proquest_miscellaneous_19993213 pascalfrancis_primary_19204194 pubmedcentral_primary_oai_pubmedcentral_nih_gov_2151409 crossref_primary_10_1128_AAC_00175_07 highwire_asm_aac_51_11_4029 |
| PublicationCentury | 2000 |
| PublicationDate | 2007-11-00 |
| PublicationDateYYYYMMDD | 2007-11-01 |
| PublicationDate_xml | – month: 11 year: 2007 text: 2007-11-00 |
| PublicationDecade | 2000 |
| PublicationPlace | Washington, DC |
| PublicationPlace_xml | – name: Washington, DC – name: United States |
| PublicationTitle | Antimicrobial Agents and Chemotherapy |
| PublicationTitleAbbrev | AAC |
| PublicationTitleAlternate | Antimicrob Agents Chemother |
| PublicationYear | 2007 |
| Publisher | American Society for Microbiology American Society for Microbiology (ASM) |
| Publisher_xml | – name: American Society for Microbiology – name: American Society for Microbiology (ASM) |
| References | (e_1_3_2_2_2) 1998; 2 e_1_3_2_26_2 e_1_3_2_20_2 e_1_3_2_21_2 e_1_3_2_22_2 e_1_3_2_23_2 e_1_3_2_24_2 e_1_3_2_25_2 e_1_3_2_9_2 e_1_3_2_15_2 e_1_3_2_8_2 e_1_3_2_16_2 e_1_3_2_7_2 e_1_3_2_17_2 e_1_3_2_6_2 e_1_3_2_19_2 e_1_3_2_10_2 e_1_3_2_5_2 e_1_3_2_11_2 e_1_3_2_4_2 e_1_3_2_12_2 e_1_3_2_3_2 e_1_3_2_13_2 e_1_3_2_14_2 (e_1_3_2_18_2) 1973 |
| References_xml | – ident: e_1_3_2_7_2 doi: 10.1128/AAC.49.8.3182-3186.2005 – ident: e_1_3_2_17_2 doi: 10.1128/IAI.72.1.62-65.2004 – ident: e_1_3_2_6_2 doi: 10.1128/AAC.46.10.3193-3196.2002 – ident: e_1_3_2_9_2 doi: 10.1128/IAI.68.2.877-883.2000 – ident: e_1_3_2_10_2 doi: 10.1128/AAC.00052-06 – ident: e_1_3_2_24_2 doi: 10.1016/S0140-6736(99)01156-3 – ident: e_1_3_2_3_2 doi: 10.1128/AAC.45.11.3109-3112.2001 – ident: e_1_3_2_11_2 – ident: e_1_3_2_16_2 doi: 10.1128/AAC.42.8.2070 – ident: e_1_3_2_22_2 doi: 10.1128/JCM.38.4.1482-1487.2000 – ident: e_1_3_2_23_2 doi: 10.1093/jac/45.2.231 – volume: 2 start-page: 81 year: 1998 ident: e_1_3_2_2_2 publication-title: Trop. Dr. – ident: e_1_3_2_26_2 – ident: e_1_3_2_15_2 doi: 10.1016/0140-6736(90)92581-2 – ident: e_1_3_2_12_2 doi: 10.1001/archderm.1974.01630110073023 – ident: e_1_3_2_14_2 doi: 10.1128/AAC.47.4.1228-1232.2003 – ident: e_1_3_2_4_2 doi: 10.3201/eid1104.041000 – ident: e_1_3_2_19_2 doi: 10.1128/jcm.35.7.1696-1700.1997 – start-page: 873 year: 1973 ident: e_1_3_2_18_2 publication-title: Lancet – ident: e_1_3_2_25_2 – ident: e_1_3_2_21_2 doi: 10.1128/JCM.37.4.1018-1023.1999 – ident: e_1_3_2_5_2 doi: 10.1128/AAC.44.9.2367-2372.2000 – ident: e_1_3_2_20_2 doi: 10.1016/S1473-3099(06)70464-9 – ident: e_1_3_2_8_2 doi: 10.1126/science.283.5403.854 – ident: e_1_3_2_13_2 doi: 10.1016/S0924-8579(03)00240-1 |
| SSID | ssj0006590 |
| Score | 2.3779306 |
| Snippet | Classifications
Services
AAC
Citing Articles
Google Scholar
PubMed
Related Content
Social Bookmarking
CiteULike
Delicious
Digg
Facebook
Google+
Mendeley
Reddit... According to recommendations of the 6th WHO Advisory Committee on Buruli ulcer, directly observed treatment with the combination of rifampin and streptomycin,... ABSTRACT According to recommendations of the 6th WHO Advisory Committee on Buruli ulcer, directly observed treatment with the combination of rifampin and... |
| SourceID | pubmedcentral proquest crossref asm2 pubmed pascalfrancis highwire |
| SourceType | Open Access Repository Aggregation Database Index Database Publisher |
| StartPage | 4029 |
| SubjectTerms | Adolescent Adult Anti-Bacterial Agents - therapeutic use Antibiotics. Antiinfectious agents. Antiparasitic agents Bacterial diseases Biological and medical sciences Buruli Ulcer Buruli Ulcer - drug therapy Buruli Ulcer - pathology Buruli Ulcer - surgery Clinical Therapeutics Drug Therapy, Combination Female Human bacterial diseases Humans Infectious diseases Male Medical sciences Middle Aged Mycobacterium ulcerans Mycobacterium ulcerans - drug effects Pharmacology. Drug treatments Rifampin Rifampin - therapeutic use Streptomycin Streptomycin - therapeutic use Survival Analysis Treatment Outcome Tuberculosis and atypical mycobacterial infections |
| Title | Promising Clinical Efficacy of Streptomycin-Rifampin Combination for Treatment of Buruli Ulcer (Mycobacterium ulcerans Disease) |
| URI | http://aac.asm.org/content/51/11/4029.abstract https://www.ncbi.nlm.nih.gov/pubmed/17526760 https://journals.asm.org/doi/10.1128/AAC.00175-07 https://search.proquest.com/docview/19993213 https://search.proquest.com/docview/68411308 https://pubmed.ncbi.nlm.nih.gov/PMC2151409 |
| Volume | 51 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3dj9MwDLfYJBAvCMbHlYMRITiBdL21XdOmj2O3EwgNTbCTeIvcJhWV1m7arg974l_HSVvGEPfCa5tYTW3Hduz8DPBG-7mOMu27SObdDVNULibaVFlw4Y_DjGyQbWL7Lf7yXVzODEwO7-7C2KL9LC0uqlV5URU_bG3lpsxGXZ3YaDGfGjNFccmoBz3yDbsQvd1-I94crJAtdUPhhV21eyBGk8nUZB5i7nq2-V7Mgyg24JR93JXBsWXq0IJNsSTu6H_lTaOLf3mifxdU_mGhrh7Cg9a1ZJNmCY_gjq4GcLdpNrkfwL15m0YfwNmiAazen7Pl4f7V7pydscUBynr_GH4utmsSBDJvrAUQXbGZAZ2guWydM5PT3tysyz3Rdb8WOZabomK0x1C8bVnOyCdmy66Y3Uz5UG_rVcGuV5nesnfzfUYbigWMrktWm4dkO9llkzZ6_wSur2bL6Ue3bdngYmhApbQ3VsRdL0WKS33FMQ1C1EoEiVIqVVx7fh4qDATGOs0VSRD3MENFThkabMLxU-hX60qfAFMqEwHmPEZFXg7GKBC9BOOMRzrnPHLgteGabHVuJ204EwhJXJaWy9KLHXjb8VRuGviOW8addgyXRFUiZpL7NE7SOhIHhkcycCCVBF7oJ6EDrzqhkMQVk3PBSq9r-ihywMeBP759RCRCnxwJ4cCzRogO1Fv5dCA-Eq_fAww0-PEb0hgLEd5qyPP_nnkK9-0ptr11-QL6N9tav4TeTtVDCjw-fR5apfsFqHQxCw |
| link.rule.ids | 230,315,729,782,786,887,27935,27936,53803,53805 |
| linkProvider | National Library of Medicine |
| linkToHtml | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEB7RIB4XHuFlCu0KQQVS3fi1fhxDmqqIpooglbitxt61iBQ7UVwfcuKvM7u2CUH00qt3d2R7v92Z2Zn9BuC9cnMVZsq1kdS7HaQobUyUzrLgsesHGekgU8T2e3T5Iz4da5oc3t2FMUn7WTo_KRfFSTn_aXIrV0U26PLEBtPJSKsp8ksGe3CX1qvjd056uwGHvDlaIW1qB7ETdPnuXjwYDkc69hBx2zHl9yLuhZGmp-xhVXi7uqnjC9bpkljRH8ubUhf_s0X_Tan8S0edPb7l1z2BR61RyoZN81O4o8o-3GvKVG76cH_SBuD7cDRtqK43x2y2vblVHbMjNt2SYG-ewa_pekkQIsXIWurRBRtrugoay5Y509Hw1fWy2JBc-9s8x2I1LxntTuSpG7AwsqbZrEuD10M-1-t6MWdXi0yt2cfJJqOtyFBN1wWr9UPSuuy0CTh9eg5XZ-PZ6Nxuiz3YGGg6KuX4knDhpEgerSs5pl6ASsZeIqVMJVeOmwcSvRgjleaSsMcdzFCSOYea1dB_Ab1yWapXwKTMYg9zHqEk-wgjjBGdBKOMhyrnPLTgnZ5t0a7WShhHyIsFoUMYdAgnsuBDhwWxaog_bui33wFFkFSBmAnuUj9B35FYcLCDna2oxHMCNwksOOzAJGhWdLQGS7Ws6aXIdPc917-5RxgHLpkgsQUvG_Btpbe4tiDageWfDppUfLeF0GjIxVv0vb71yEN4cD6bXIiLL5df9-GhOQs3dzffQO96Xau3sFfJ-sAs2d9aEkWT |
| linkToPdf | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lj9MwEB6xRay48CivsLBrIViBtNkmaZzHsfQhEHRVQVfamzWJHRGpSat2c-iJv87YSbYUsRe4JmMrjj97ZjzjbwDeKjdTQapcG0m9236C0sZY6SwLHrl9PyUdZIrYfg8vrqLRWNPk3JT6Mkn7aZKfl4vivMx_mNzKVZH22jyx3mw61GqK_JLeSma9A7hLa9bhraPebMIBr49XSKPafuT4bc67F_UGg6GOP4TcdkwJvpB7QagpKju4Kbx9_dRyBuuUSdzQX8vqchd_s0f_TKv8TU9NHv7HCB_Bg8Y4ZYNa5DHcUWUX7tXlKrddOJw2gfgunM5qyuvtGZvvbnBtztgpm-3IsLdP4OdsvSQokYJkDQXpgo01bQW1ZcuM6aj46npZbKlf-1ueYbHKS0a7FHnsBjSMrGo2b9PhdZOP1bpa5Oxykao1ez_dprQlGcrpqmCVfkjal43qwNOHp3A5Gc-Hn-ym6IONvqalUk5fEj6cBMmzdSXHxPNRyciLpZSJ5MpxM1-iF2GokkwSBrmDKUoy61CzG_afQadcluoFMCnTyMOMhyjJTsIQI0QnxjDlgco4Dyx4o2dcNKt2I4xD5EWCECIMQoQTWvCuxYNY1QQgt8gdtWAR1KtATAV3SU7QOGILjvfws-sq9hzfjX0LTlpACZoVHbXBUi0r-igy4fue279dIoh8l0yRyILnNQB3vTfYtiDcg-aNgCYX339DiDQk4w0CX_5zyxM4nI0m4uvniy9HcN8ciZsrnK-gc72u1Gs42Mjq2KzaX3UDSBM |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Promising+Clinical+Efficacy+of+Streptomycin-Rifampin+Combination+for+Treatment+of+Buruli+Ulcer+%28Mycobacterium+ulcerans+Disease%29&rft.jtitle=Antimicrobial+agents+and+chemotherapy&rft.au=Chauty%2C+Annick&rft.au=Ardant%2C+Marie-Francoise&rft.au=Adeye%2C+Ambroise&rft.au=Euverte%2C+Helene&rft.date=2007-11-01&rft.issn=0066-4804&rft.eissn=1098-6596&rft.volume=51&rft.issue=11&rft.spage=4029&rft.epage=4035&rft_id=info:doi/10.1128%2Faac.00175-07&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0066-4804&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0066-4804&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0066-4804&client=summon |